|
1
|
Becker N: Epidemiology of multiple
myeloma. Recent Results Cancer Res. 183:25–35. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Martin T and Huff CA: Multiple myeloma:
Current advances and future directions. Clin Lymphoma Myeloma Leuk.
19:255–263. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Howlader N NA, Krapcho M, Miller D, Bishop
K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al: SEER
Cancer Statistics Review, 1975–2013, National Cancer Institute
Bethesda, MD, based on November 2015 SEER data submission, posted
to the SEER website, 2016. https://seer.cancer.gov/archive/csr/1975_2013/April
20–2016
|
|
4
|
Cid Ruzafa J, Merinopoulou E, Baggaley RF,
Leighton P, Werther W, Felici D and Cox A: Patient population with
multiple myeloma and transitions across different lines of therapy
in the USA: An epidemiologic model. Pharmacoepidemiol Drug Saf.
25:871–879. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Varga C, Maglio M, Ghobrial IM and
Richardson PG: Current use of monoclonal antibodies in the
treatment of multiple myeloma. Br J Haematol. 181:447–459. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Crona M, Codó P, Jonna VR, Hofer A,
Fernandes AP and Tholander F: A ribonucleotide reductase inhibitor
with deoxyribonucleoside-reversible cytotoxicity. Mol Oncol.
10:1375–1386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aye Y, Li M, Long MJ and Weiss RS:
Ribonucleotide reductase and cancer: Biological mechanisms and
targeted therapies. Oncogene. 34:2011–2021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shao J, Liu X, Zhu L and Yen Y: Targeting
ribonucleotide reductase for cancer therapy. Expert Opin Ther
Targets. 17:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morikawa T, Hino R, Uozaki H, Maeda D,
Ushiku T, Shinozaki A, Sakatani T and Fukayama M: Expression of
ribonucleotide reductase M2 subunit in gastric cancer and effects
of RRM2 inhibition in vitro. Hum Pathol. 41:1742–1748. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morikawa T, Maeda D, Kume H, Homma Y and
Fukayama M: Ribonucleotide reductase M2 subunit is a novel
diagnostic marker and a potential therapeutic target in bladder
cancer. Histopathology. 57:885–892. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang L, Meng L, Wang XW, Ma GY and Chen
JH: Expression of RRM1 and RRM2 as a novel prognostic marker in
advanced non-small cell lung cancer receiving chemotherapy. Tumour
Biol. 35:1899–1906. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
D'Angiolella V, Donato V, Forrester FM,
Jeong YT, Pellacani C, Kudo Y, Saraf A, Florens L, Washburn MP and
Pagano M: Cyclin F-mediated degradation of ribonucleotide reductase
M2 controls genome integrity and DNA repair. Cell. 149:1023–1034.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dai L, Lin Z, Qiao J, Chen Y, Flemington
EK and Qin Z: Ribonucleotide reductase represents a novel
therapeutic target in primary effusion lymphoma. Oncogene.
36:5068–5074. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kang W, Tong JH, Chan AW, Zhao J, Wang S,
Dong Y, Sin FM, Yeung S, Cheng AS, Yu J and To K: Targeting
ribonucleotide reductase M2 subunit by small interfering RNA exerts
anti-oncogenic effects in gastric adenocarcinoma. Oncol Rep.
31:2579–2586. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang N, Li Y and Zhou J: Downregulation of
ribonucleotide reductase subunits M2 induces apoptosis and G1
arrest of cervical cancer cells. Oncol Lett. 15:3719–3725.
2018.PubMed/NCBI
|
|
16
|
Shah KN, Wilson EA, Malla R, Elford HL and
Faridi JS: Targeting ribonucleotide reductase M2 and NF-κB
activation with didox to circumvent tamoxifen resistance in breast
cancer. Mol Cancer Ther. 14:2411–2421. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Elbashir SM, Harborth J, Lendeckel W,
Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs
mediate RNA interference in cultured mammalian cells. Nature.
411:494–498. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin ZP, Belcourt MF, Cory JG and
Sartorelli AC: Stable suppression of the R2 subunit of
ribonucleotide reductase by R2-targeted short interference RNA
sensitizes p53(−/-) HCT-116 colon cancer cells to DNA-damaging
agents and ribonucleotide reductase inhibitors. J Biol Chem.
279:27030–27038. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: RNA interference targeting the M2 subunit of
ribonucleotide reductase enhances pancreatic adenocarcinoma
chemosensitivity to gemcitabine. Oncogene. 23:1539–1548. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang P, Yan R, Zhang X, Wang L, Ke X and
Qu Y: Activating Wnt/β-catenin signaling pathway for disease
therapy: Challenges and opportunities. Pharmacol Ther. 196:79–90.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
van Andel H, Kocemba KA, Spaargaren M and
Pals ST: Aberrant Wnt signaling in multiple myeloma: Molecular
mechanisms and targeting options. Leukemia. 33:1063–1075. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu L, Zhou B, Chen X, Jiang H, Shao J and
Yen Y: Inhibitory mechanisms of heterocyclic carboxaldehyde
thiosemicabazones for two forms of human ribonucleotide reductase.
Biochem Pharmacol. 78:1178–1185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Agnelli L, Forcato M, Ferrari F, Tuana G,
Todoerti K, Walker BA, Morgan GJ, Lombardi L, Bicciato S and Neri
A: The reconstruction of transcriptional networks reveals critical
genes with implications for clinical outcome of multiple myeloma.
Clin Cancer Res. 17:7402–7412. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Furukawa Y and Kikuchi J: Molecular
pathogenesis of multiple myeloma. Int J Clin Oncol. 20:413–422.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mimura N, Hideshima T and Anderson KC:
Novel therapeutic strategies for multiple myeloma. Exp Hematol.
43:732–741. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li J, Pang J, Liu Y, Zhang J, Zhang C,
Shen G and Song L: Suppression of RRM2 inhibits cell proliferation,
causes cell cycle arrest and promotes the apoptosis of human
neuroblastoma cells and in human neuroblastoma RRM2 is suppressed
following chemotherapy. Oncol Rep. 40:355–360. 2018.PubMed/NCBI
|
|
28
|
Li C, Zheng J, Chen S, Huang B, Li G, Feng
Z, Wang J and Xu S: RRM2 promotes the progression of human
glioblastoma. J Cell Physiol. 233:6759–6767. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mannarqudi MB and Deb S: Clinical
pharmacology and clinical trials of ribonucleotide reductase
inhibitors: Is it a viable cancer therapy? J Cancer Res Clin Oncol.
143:1499–1529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mahler M, Miyachi K, Peebles C and
Fritzler MJ: The clinical signifcance of autoantibodies to the
proliferating cell nuclear antigen (PCNA). Autoimmun Rev.
11:771–775. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Solier S and Pommier Y: The nuclear γ-H2AX
apoptotic ring: Implications for cancers and autoimmune diseases.
Cell Mol Life Sci. 71:2289–2297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Khalilzadeh B, Shadjou N, Kanberoglu GS,
Afsharan H, de la Guardia M, Charoudeh HN, Ostadrahimi A and
Rashidi MR: Advances in nanomaterial based optical biosensing and
bioimaging of apoptosis via caspase-3 activity: A review. Mikrochim
Acta. 185:4342018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Morales J, Li L, Fattah FJ, Dong Y, Bey
EA, Patel M, Gao J and Boothman DA: Review of poly (ADP-ribose)
polymerase (PARP) mechanisms of action and rationale for targeting
in cancer and other diseases. Crit Rev Eukaryot Gene Expr.
24:15–28. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Reya T and Clevers H: Wnt signalling in
stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tammela T, Sanchez-Rivera FJ, Centinbas
NM, Wu K, Joshi NS, Helenius K, Park Y, Azimi R, Kerper NR,
Wesselhoeft RA, et al: A Wnt-producing niche drives proliferative
potential and progression in lung adenocarcinoma. Nature.
545:355–359. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ren Z, van Andel H, de Lau W, Hartholt RB,
Maurice MM, Clevers H, Kersten MJ, Spaargaren M and Pals ST:
Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by
presenting Wnts and R-spondins. Blood. 131:982–994. 2018.
View Article : Google Scholar : PubMed/NCBI
|
